Pricing Log in Create free account
Saturday 17 October 2026 Export QTTB’s income statement to Excel — free account

Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.52 0.25 −3.22%
Market cap
$231.3M
P/E
2.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
n/a
Altman Z
−0.78
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 30.00
Total sells 0.51
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 2 — — — — —
Sell — 2 — 3 — — — — — 3 — 3
Insider Ownership 5.42%

Capital & Financial Ratios $m

Market Cap 231.31
Revenue (6.65)
Net Income 33.79
Free Cash Flow (19.83)
Net Debt (106.27)
Current Ratio 20.30 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 2.49
Fwd P/E (7.22) (negative: loss-making)
P/S ratio 0.00
P/B ratio 1.44
Past 5Y EPS Growth —
This Y EPS Growth (161.21%) (below 0%: weak)
Next Y EPS Growth (47.98%) (below 0%: weak)
Next Y revenue growth (99.38%) (below 0%: weak)
Next 5Y EPS Growth 9.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −8.3×, against a ten-year median of 2.3×; over the ten years it ranged from −74.3× in 2024 to 366× in 2019.
P/B against its own 10 years 34.41%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 26 78 48 106
Receivables — — — —
Inventory — — — —
Other — — — —
29 82 55 110
2023 2024 2025 Q'26
Payables 3 3 1 2
ST’ Debt 1 3 6 —
Other — 3 — —
14 16 11 5

Compound Annual Growth %

10y 5y 3y
Sales — 100.32% 16.52%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (26.51%) (38.20%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 54
’23 3 3 2 (15) (7)
’22 1 1 1 1 3
’21 29 2 2 1 34
’20 1 1 1 1 3
’19 0 0 0 1 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (3) — — —
’25 (12) (11) (4) (6) (34)
’24 (15) (22) (20) (11) (68)
’23 (12) (11) 16 (11) (19)
’22 (31) (31) (25) (27) (114)
’21 (30) (24) (25) (30) (110)
’20 (26) (28) (29) (12) (94)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (3) — — —
’25 (12) (11) (4) 1 (27)
’24 (15) (22) (20) (11) (68)
’23 (13) (11) 16 (11) (19)
’22 (32) (31) (25) (27) (115)
’21 (31) (25) (26) (31) (112)
’20 (28) (29) (29) (13) (98)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.54) (0.44) — — —
’25 (0.90) (0.78) (0.60) 4.58 2.42
’24 0.44 (1.42) (1.46) (1.16) (4.94)
’23 (19.84) (16.69) (40.52) (76.91) (153.96)
’22 28.60 (9.17) (10.61) (10.79) (1.62)
’21 (0.36) (9.71) (9.71) (10.61) (31.11)
’20 (14.03) (14.03) (11.15) (11.15) (50.36)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 271.26 198.90 156.60 64.98 18.72 8.24 3.02 1.35

Analyst estimates 2026–2028

Powerpack
High — — 477.00 572.40 402.84 274.32 76.68 31.68 53.79 6.37
People
People Employees — 67 124 187 205 224 92 7 42 24
Revenue/emp, $m — 0.00 0.04 0.01 0.01 0.15 0.03 (0.95) 0.00 2.24
Income, $m
Income, $m Revenue — — 5 2 3 34 3 (7) — 54
Gross margin, % 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00
EBT (8) (30) (56) (104) (129) (96) 1 (53) (46) 30
EBT margin, % 0.00 0.00 (1,044.29) (6,237.45) (4,762.92) (281.90) 37.34 803.26 0.00 55.49
Net income (8) (30) (56) (104) (129) (96) (5) (54) (48) 30
Depreciation 0 1 1 6 8 9 (1) 1 0 1
Per share, $
Per share, $ Revenue 0.00 0.00 3.35 0.71 1.06 11.05 1.01 (19.05) 0.00 4.37
Earnings (76.13) (217.59) (35.97) (44.42) (50.36) (31.11) (1.62) (153.96) (5.12) 2.42
Cash flow (80.27) 47.02 (26.81) (39.01) (36.96) (35.71) (35.61) (53.50) (7.26) (2.73)
Capex (18.82) (14.21) (15.71) (9.32) (1.46) (0.78) (0.40) (0.01) (0.01) 0.57
Free cash flow (99.09) 32.81 (42.52) (48.33) (38.42) (36.48) (36.02) (53.51) (7.27) (2.16)
Book value 70.96 713.41 123.69 110.39 76.78 55.19 55.77 (204.74) 0.61 3.42
Shares, m 0 0 2 2 3 3 3 0 9 12
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 — 1.43
P/S — — 120.06 523.74 191.98 5.93 21.49 0.00 — 0.00
P/B — — 3.25 3.38 2.65 1.19 0.39 0.00 — 0.97
EV/Sales — — 79.71 366.25 117.23 2.04 (23.88) (3.34) — (0.34)
EV/FCF — — (6.28) (5.39) (3.23) (0.62) 0.67 (1.19) — (0.08)
Cash, $m
Cash, $m Operating cash flow (8) 6 (43) (91) (94) (110) (114) (19) (68) (34)
Capex (2) (2) (25) (22) (4) (2) (1) 0 0 7
Free cash flow (10) 5 (68) (113) (98) (112) (115) (19) (68) (27)
Balance, $m
Balance, $m Working capital 6 123 199 254 197 175 158 15 65 44
Total debt — — — — 15 24 29 44 13 10
Net debt (11) (130) (215) (262) (202) (132) (146) 18 (65) (39)
Shareholders’ equity 8 98 196 259 196 170 178 (71) 6 42
Returns, %
Returns, % ROA (10.61) (39.53) (28.03) (36.48) (44.82) (40.28) (2.27) (39.01) (68.49) 38.70
ROIC 0.00 0.00 0.00 0.00 0.00 (159.02) (256.87) 0.00 0.00 308.43
ROE 32.61 121.55 (70.84) (45.69) (56.63) (52.38) (2.88) 2,174.51 53.86 125.06
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2023

Charts ten years each

Q32 Bio Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BBOT BridgeBio Oncology Therapeutics, Inc $236.5M — (loss-making) — — n/m −88.78% (below 0%: shrinking) — 0.00% Compare
SABS SAB Biotherapeutics, Inc. $235.7M — (loss-making) 19.9× −90.95% (below 0%: shrinking) n/m −59.75% (below 0%: shrinking) 100.00% 0.00% Compare
IMRX Immuneering Corporation $235.5M — (loss-making) — (loss-making) −99.74% (below 0%: shrinking) n/m −74.94% (below 0%: shrinking) 0.00% 0.00% Compare
QTTB Q32 Bio Inc. $231.3M 2.5× — (loss-making) −1,928.18% (below 0%: shrinking) n/m +71.13% (above 0%: growing) 100.00% 0.00%
FATE Fate Therapeutics, Inc. $230.7M — (loss-making) — (loss-making) +9.18% (above 0%: growing) n/m +8.96% (above 0%: growing) 100.00% (1,495.39%) Compare
LXEO Lexeo Therapeutics, Inc. $226.6M — (loss-making) — (loss-making) — n/m +35.58% (above 0%: growing) 0.00% 0.00% Compare
SLGL Sol-Gel Technologies Ltd. $224.9M — (loss-making) — (loss-making) −96.58% (below 0%: shrinking) n/m −8.76% (below 0%: shrinking) 100.00% (704.23%) Compare
GLSI Greenwich LifeSciences, Inc. $224.9M — (loss-making) — — n/m +13.14% (above 0%: growing) 0.00% 0.00% Compare
KROS Keros Therapeutics, Inc. $220.1M — (loss-making) — (loss-making) −99.83% (below 0%: shrinking) n/m +32.19% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $228.6M — — −96.58% — +0.10% 100.00% 0.00%

All 614 Biotechnology stocks →

Q32 Bio Inc. (QTTB) key facts

  • Q32 Bio Inc. (QTTB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.
  • As of October 16, 2026, QTTB traded at $7.52, a market capitalization of $231.3 million.
  • Return on equity was 125.1% and debt-to-equity 0.00.
  • Its Altman Z-score is −0.78 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Q32 Bio Inc. (QTTB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/QTTB · Data as of Dec 31, 2023 · For information only; not investment advice. · © 2026 stockrow.com